Oncotarget

Research Papers:

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer

Vanita Noronha, Vijay Maruti Patil, Amit Joshi, Manoj Mahimkar, Usha Patel, Manish Kumar Pandey, Arun Chandrasekharan, Hollis Dsouza, Atanu Bhattacharjee, Abhishek Mahajan, Nilesh Sabale, Jai Prakash Agarwal, Sarbani Ghosh-Laskar, Ashwini Budrukkar, Anil K. D’Cruz, Pankaj Chaturvedi, Prathamesh S. Pai, Devendra Chaukar, Sudhir Nair, Shivakumar Thiagarajan, Shripad Banavali and Kumar Prabhash _

Metrics: PDF 844 views  |   Full Text 1899 views  |   ?  


Abstract

Vanita Noronha1,*, Vijay Maruti Patil1,*, Amit Joshi1, Manoj Mahimkar2, Usha Patel2, Manish Kumar Pandey2, Arun Chandrasekharan1, Hollis Dsouza1, Atanu Bhattacharjee3, Abhishek Mahajan1, Nilesh Sabale1, Jai Prakash Agarwal4, Sarbani Ghosh-Laskar4, Ashwini Budrukkar4, Anil K. D’Cruz5, Pankaj Chaturvedi5, Prathamesh S. Pai5, Devendra Chaukar5, Sudhir Nair5, Shivakumar Thiagarajan5, Shripad Banavali1 and Kumar Prabhash1

1 Department of Medical Oncology, Tata Memorial Hospital, HBNI, Mumbai, India

2 Mahimkar Laboratory, Cancer Research Institute (CRI), Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), HBNI, Navi Mumbai, India

3 Section of Biostatistics, Department of Epidemiology, Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India

4 Department of Radiation Oncology, Tata Memorial Hospital, HBNI, Mumbai, India

5 Department of Head and Neck Surgery, Tata Memorial Hospital, HBNI, Mumbai, India

* These authors contributed equally to this work

Correspondence to:

Kumar Prabhash,email: kumarprabhashtmh@gmail.com

Keywords: HPV negative; oropharynx; nimotuzumab; weekly; cisplatin

Received: September 03, 2019     Accepted: December 21, 2019     Published: January 28, 2020

ABSTRACT

Background: Addition of nimotuzumab to weekly cisplatin and radiation improves outcomes in head and neck cancer. HPV negative oropharyngeal cancer has unsatisfactory treatment outcomes and is a candidate for escalation of treatment. We wanted to determine whether the addition of nimotuzumab to cisplatin-radiation could improve outcomes in these poor-risk tumors.

Methods: This was a subgroup analysis of a phase 3 randomized study. In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin (30 mg/m2 IV)- radiation (66–70 Gy) {CRT arm} or nimotuzumab (200 mg weekly) -weekly cisplatin (30 mg/m2)-radiation (66–70 Gy) {NCRT arm}. The data of HPV negative oropharyngeal cancer was extracted from the database of this study for the analysis. HPV testing was done with p16 immunohistochemistry (IHC) staining and reported according to the CAP criteria. The outcomes assessed were progression-free survival (PFS), disease-free survival (DFS), locoregional control, and overall survival (OS). Interaction test was performed between the study arms and HPV status prior to doing any HPV specific analysis for each of the studied outcomes. Kaplan Meier estimates for 2 year OS with 95%CI was calculated. The hazard ratio was obtained using COX regression analysis.

Results: We had 187 HPV negative oropharyngeal cancers, 91 in the CRT arm and 96 in NCRT arm. The interaction test was significant for PFS (p = 0.000), locoregional control (p = 0.007) and overall survival (p = 0.002) but not for DFS (p = 0.072). The 2- year PFS was 31.5% (95%CI 21.5–42) in CRT arm versus 57.2% (95%CI 45.8–67.1) in NCRT arm (HR -0.54; 95%CI 0.36–0.79, p = 0.002). The 2-year LRC was 41.4% (95%CI 29.8–52.6) in the CRT arm versus in 60.4% (95%CI 48.7–70.2) in the NCRT arm (HR -0.61; 95%CI 0.4–0.94, p = 0.024). The addition of nimotuzumab also lead to an improvement in 2-year OS from 39.0% (95%CI 28.4–49.6) to 57.6% (95%CI 46.3–67.4) (HR-0.63, 95%CI 0.43–0.92, p = 0.018).

Conclusions: The addition of nimotuzumab to weekly cisplatin-radiation improves outcomes inclusive of OS in HPV negative oropharyngeal cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27443